FindTrial
Sign In

Understanding Treatment Phase at ICU Admission in Children with Blood Cancers

Implications of Phase of treatment at ICU admission in critically ill children with haematological malignancy - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/076080
Enrollment
250
Registered
2024-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Nil: NA Control Intervention1: Nil: NA

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children less than 18 years with provisional or under evaluation or confirmed diagnosis of acute leukemia AML and ALL admitted in Medical or Surgical ICU from January 2022 to December 2022

Exclusion criteria

Exclusion criteria: Children admitted for supportive care those expected to die within 24 hours of ICU admission and patients admitted after a Blue code

Design outcomes

Primary

MeasureTime frame
To determine the mortality rate at various oncological stages of treatment in the acute leukaemia paediatric populations in an ICU setup of tertiary care cancer centreTimepoint: Until ICU discharge and at 90 days of ICU admission—

Secondary

MeasureTime frame
- Length of stay - 90-day survival and 1 year survival of children admitted at induction in ICU - 90-day survival and 1 year survival of children admitted at other stages in ICU - To determine the cause of death in ICUTimepoint: Until ICU discharge and at 90 days of ICU admission—

Countries

India

Contacts

Public ContactDr Sudivya Sharma

Tata Memorial Hospital

drsudivyasharma@gmail.com9892762615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026